Grufity logoGrufity logo

RECURSION PHARMACEUTICALS, INC. Stock Research

RXRX

7.48USD-0.15(-1.97%)Market Closed

Market Summary

USD7.48-0.15
Market Closed
-1.97%

RXRX Alerts

RXRX Stock Price

RXRX RSI Chart

RXRX Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-5.97

Price/Sales (Trailing)

35.86

Price/Free Cashflow

-11.85

RXRX Price/Sales (Trailing)

RXRX Profitability

Return on Equity

-49.29%

Return on Assets

-34.15%

Free Cashflow Yield

-8.44%

RXRX Fundamentals

RXRX Revenue

Revenue (TTM)

39.8M

Revenue Y/Y

439.91%

Revenue Q/Q

3.92%

RXRX Earnings

Earnings (TTM)

-239.5M

Earnings Y/Y

11.46%

Earnings Q/Q

4.89%

Price Action

52 Week Range

4.9214.18
(Low)(High)

Last 7 days

-7.6%

Last 30 days

-6.3%

Last 90 days

-11.7%

Trailing 12 Months

19.7%

RXRX Financial Health

Current Ratio

5.68

Debt/Equity

0

Debt/Cashflow

-108.49

RXRX Investor Care

Shares Dilution (1Y)

12.19%

Diluted EPS (TTM)

-1.36

Financials for RECURSION PHARMACEUTICALS

Income Statement (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue38.8%39,84328,70018,07412,94910,178
Operating Expenses-192,953----
  S&GA Expenses0.8%81,59980,96277,16469,81957,682
  R&D Expenses-2.7%155,696160,008152,418143,603135,271
Interest Expenses-3.5%55.0057.00168440680
Net Income3.0%-239,476-246,917-233,900-211,741-186,479
Net Income Margin30.1%-6.01*-8.60*-10.38*-3.94*-18.32*
Free Cahsflow9.7%-120,583-133,478-113,428-75,195-198,412
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets14.7%701612673734610
  Current Assets18.3%570482546619535
    Cash Equivalents21.0%550455454508285
  Net PPE2.8%88.0086.0082.0071.0065.00
  Goodwill0%1.001.001.001.001.00
Liabilities-3.6%21522323524167.00
  Current Liabilities20.7%10083.0097.0086.0047.00
  Long Term Debt-1.00----
Shareholder's Equity25.2%486388438494543
  Retained Earnings-9.9%-639-582-521-456-400
  Additional Paid-In Capital16.0%1,125970959950943
Shares Outstanding9.7%191174173171170
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations16.4%-83.52-99.93-78.44-50.47-158
  Share Based Compensation13.7%28.0025.0019.0019.0015.00
Cashflow From Investing29.7%193149-97.87-109-271
Cashflow From Financing1318.0%15411.00-2.55458459

Risks for RXRX

What is the probability of a big loss on RXRX?

96.0%


Probability that RECURSION PHARMACEUTICALS stock will be more than 20% underwater in next one year

96.0%


Probability that RECURSION PHARMACEUTICALS stock will be more than 30% underwater in next one year.

83.2%


Probability that RECURSION PHARMACEUTICALS stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RXRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if RECURSION PHARMACEUTICALS was unfortunately bought at previous high price.

Drawdowns

Returns for RXRX

Cumulative Returns on RXRX

Which funds bought or sold RXRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
BAILLIE GIFFORD & CO
added
14.94
-38,398,200
191,369,000
0.20%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
9.41
-26,251
101,749
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-67.51
-59,000
18,000
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
-154,415
405,585
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
6.08
-405,000
1,345,000
0.01%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-52,000
-
-%
2023-02-15
MetLife Investment Management, LLC
unchanged
-
-211,639
556,361
-%
2023-02-15
ALLIANCEBERNSTEIN L.P.
reduced
-87.93
-31,433,400
3,011,560
-%
2023-02-15
JANE STREET GROUP, LLC
reduced
-21.52
-158,113
208,887
-%
2023-02-15
Metropolitan Life Insurance Co/NY
unchanged
-
-24,429
64,571
-%

1–10 of 47

Latest Funds Activity

Are funds buying RXRX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own RXRX
No. of Funds

RECURSION PHARMACEUTICALS News

Defense World

Kentucky Retirement Systems Has $5.66 Million Stake in The ....

Defense World,
23 hours ago

Defense World

Defense World

Defense World

Defense World

Schedule 13G FIlings of RECURSION PHARMACEUTICALS

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
lux capital management, llc
3.3%
6,004,722
SC 13G/A
Feb 09, 2023
vanguard group inc
5.54%
10,057,363
SC 13G
Feb 03, 2023
blackrock inc.
5.9%
10,667,624
SC 13G
Jan 24, 2023
baillie gifford & co
13.66%
24,820,850
SC 13G/A
Oct 31, 2022
mubadala investment co pjsc
6.3%
11,291,937
SC 13D/A
Feb 14, 2022
data collective iv, l.p.
3.7%
5,941,120
SC 13G
Feb 14, 2022
lux capital management, llc
8.2%
13,021,519
SC 13G

RXRX Fair Value

RECURSION PHARMACEUTICALS fair value in different scenarios

The table shows the Fair Value estimates for RECURSION PHARMACEUTICALS for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

0.65

-91.31%

0.69

-90.78%

0.86

-88.50%

1.13

-84.89%

1.67

-77.67%
Current Inflation

0.64

-91.44%

0.68

-90.91%

0.83

-88.90%

1.06

-85.83%

1.53

-79.55%
Very High Inflation

0.64

-91.44%

0.67

-91.04%

0.80

-89.30%

0.99

-86.76%

1.36

-81.82%

Historical RECURSION PHARMACEUTICALS Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of RECURSION PHARMACEUTICALS

View All Filings
Date Filed Form Type Document
Mar 15, 2023
4
Insider Trading
Mar 10, 2023
4
Insider Trading
Mar 10, 2023
8-K
Current Report
Mar 09, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Feb 28, 2023
4
Insider Trading
Feb 27, 2023
10-K
Annual Report

Latest Insider Trading transactions for RXRX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-09
Gibson Christopher
sold
-116,620
7.7747
-15,000
chief executive officer
2023-03-08
Gibson Christopher
sold
-8,086
8.0867
-1,000
chief executive officer
2023-03-08
Gibson Christopher
sold
-573,925
8.096
-70,890
chief executive officer
2023-03-08
Gibson Christopher
sold
-32,361
8.0904
-4,000
chief executive officer
2023-03-08
Gibson Christopher
acquired
-
-
20,000
chief executive officer
2023-03-08
Gibson Christopher
sold
-161,900
8.095
-20,000
chief executive officer
2023-03-08
Gibson Christopher
acquired
-
-
4,000
chief executive officer
2023-03-08
Gibson Christopher
acquired
232,500
2.48
93,750
chief executive officer
2023-03-08
Gibson Christopher
acquired
-
-
1,000
chief executive officer
2023-03-08
Gibson Christopher
gifted
-
-
-10,000
chief executive officer

1–10 of 50

Chistopher C. Gibson
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

RXRX Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue   
Revenue$ 39,843$ 10,178$ 3,962
Operating costs and expenses   
Cost of revenue48,27500
Research and development155,696135,27163,319
General and administrative81,59957,68225,258
Total operating costs and expenses285,570192,95388,577
Loss from operations(245,727)(182,775)(84,615)
Other income (loss), net6,251(3,704)(2,391)
Net loss$ (239,476)$ (186,479)$ (87,006)
Per share data   
Net loss per share of Class A and B common stock, basic (in dollars per share)$ (1.36)$ (1.49)$ (3.99)
Net loss per share of Class A and B common stock, diluted (in dollars per share)$ (1.36)$ (1.49)$ (3.99)
Weighted-average shares (Class A and B) outstanding, basic (in shares)175,537,487125,348,11021,781,386
Weighted-average shares (Class A and B) outstanding, diluted (in shares)175,537,487125,348,11021,781,386
Operating revenue   
Revenue   
Revenue$ 39,681$ 10,000$ 3,413
Grant revenue   
Revenue   
Revenue$ 162$ 178$ 549

RXRX Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 549,912$ 285,116
Restricted cash1,2801,552
Accounts receivable034
Other receivables2,7539,056
Investments0231,446
Other current assets15,8697,514
Total current assets569,814534,718
Restricted cash, non-current7,9208,681
Property and equipment, net88,19264,725
Operating lease right-of-use assets33,2550
Intangible assets, net1,3061,385
Goodwill801801
Other non-current assets035
Total assets701,288610,345
Current liabilities  
Accounts payable4,5862,819
Accrued expenses and other liabilities32,90432,333
Unearned revenue56,72610,000
Notes payable9790
Operating lease liabilities5,9520
Lease incentive obligation01,416
Total current liabilities100,26546,658
Deferred rent04,110
Unearned revenue, non-current70,2616,667
Notes payable, non-current536633
Operating lease liabilities, non-current44,4200
Lease incentive obligation, non-current09,339
Total liabilities215,48267,407
Commitments and contingencies (Note 9)
Stockholders’ equity  
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of December 31, 2022 and December 31, 2021, respectively; 191,022,864 shares (Class A 183,209,655 and Class B 7,813,209) and 170,272,462 (Class A 160,906,245 and Class B 9,366,217) issued and outstanding as of December 31, 2022 and December 31, 2021, respectively22
Additional paid-in capital1,125,360943,142
Accumulated deficit(639,556)(400,080)
Accumulated other comprehensive loss0(126)
Total stockholders’ equity485,806542,938
Total liabilities and stockholders’ equity$ 701,288$ 610,345